Ningbo Menovo Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Cheng Zhi Yao

Chief executive officer

CN¥609.5k

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	5.5%
Management average tenure	no data
Board average tenure	no data

Recent management updates

Recent updates

Ningbo Menovo Pharmaceutical's (SHSE:603538) Problems Go Beyond Weak Profit

Nov 05

Benign Growth For Ningbo Menovo Pharmaceutical Co., Ltd. (SHSE:603538) Underpins Its Share Price

Apr 17

CEO

Cheng Zhi Yao (50 yo)

no data

Tenure

CN¥609,500

Compensation

Mr. Yao, Cheng Zhi serves as Chairman of the Board and General Manager at Ningbo Menovo Pharmaceutical Co., Ltd.

Ningbo Menovo Pharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

Ningbo Menovo Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Less than half of directors are independent

Recent updates

Ningbo Menovo Pharmaceutical's (SHSE:603538) Problems Go Beyond Weak Profit

Third quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.13 in 3Q 2023)

Ningbo Menovo Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: EPS: CN¥0.022 (vs CN¥0.054 loss in 2Q 2023)

Ningbo Menovo Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

New minor risk - Shareholder dilution

Ningbo Menovo Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.21 in 1Q 2023)

Benign Growth For Ningbo Menovo Pharmaceutical Co., Ltd. (SHSE:603538) Underpins Its Share Price

Ningbo Menovo Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investor sentiment deteriorates as stock falls 19%

Ningbo Menovo Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

New minor risk - Share price stability

Ningbo Menovo Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Second quarter 2023 earnings released: CN¥0.054 loss per share (vs CN¥0.33 profit in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.54 in 1Q 2022)

Investor sentiment improved over the past week

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.23 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.44 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.30 in 1Q 2020)

New 90-day low: CN¥32.00

Third quarter earnings released

New 90-day low: CN¥35.63

New 90-day low: CN¥39.20

New 90-day low - CN¥41.20

Innovative Development Guide Fund for Trade in Services (Limited Partnership) completed the acquisition of 5% stake in Ningbo Menovo Pharmaceutical Co., Ltd. (SHSE:603538) from Ningbo Menovo Holdings Co., Ltd.

Ningbo Menovo Pharmaceutical Co., Ltd. (SHSE:603538) agreed to acquire 49% stake in Xuancheng Menovo Pharmaceutical Co., Ltd. from Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd. for approximately CNY120 million.

CEO

Tenure

Compensation